Last reviewed · How we verify
VAL201
At a glance
| Generic name | VAL201 |
|---|---|
| Also known as | VAL201-001 |
| Sponsor | ValiRx Plc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose Finding Safety Study of VAL201 in Cancer Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VAL201 CI brief — competitive landscape report
- VAL201 updates RSS · CI watch RSS
- ValiRx Plc portfolio CI